6IO Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
International GrowthSustained double-digit international growth indicates that Inogen is expanding beyond its pressured U.S. channels and building broader geographic demand. Repeated growth across ten quarters supports a more durable market-positioning benefit, while diversification can reduce reliance on any single region.
Product Innovation And AdoptionEarly adoption of Voxi and Aurora demonstrates that the product pipeline is contributing measurable revenue rather than remaining purely developmental. Continued launches can refresh the portfolio, support customer acquisition, and strengthen Inogen’s ability to compete in portable respiratory care.
Liquidity And Low LeverageA debt-free balance sheet and substantial liquidity give Inogen flexibility to fund product development, geographic expansion, and operating improvements without immediate refinancing pressure. Positive quarterly cash generation also provides evidence that execution can produce internal funding, despite broader cash-flow volatility.
Bears Say
Persistent LossesRevenue and gross margin have improved, but Inogen has not yet converted that recovery into sustainable GAAP earnings. Continued operating and net losses constrain internally generated capital, make the turnaround dependent on further execution, and leave profitability vulnerable if growth or mix improvements slow.
Ongoing Cash BurnNegative trailing operating and free cash flow indicate that the business is not yet self-funding over a sustained period. If cash conversion does not improve, liquidity will increasingly support operations and investment rather than expansion, reducing the durability of the current turnaround and capital-allocation flexibility.
U.S. Channel And Rental PressureThe shift away from direct-to-consumer sales and traditional rentals is a structural channel challenge, not merely a single-quarter fluctuation. B2B growth only partly offsets the decline, which can constrain U.S. revenue quality, customer economics, and the pace at which overall growth translates into earnings.
Inogen News
6IO FAQ
What was Inogen’s price range in the past 12 months?
Currently, no data Available
What is Inogen’s market cap?
Inogen’s market cap is CHF112.22M.
When is Inogen’s upcoming earnings report date?
Inogen’s upcoming earnings report date is Nov 11, 2026 which is in 59 days.
How were Inogen’s earnings last quarter?
Inogen released its earnings results on Aug 06, 2026. The company reported -CHF0.113 earnings per share for the quarter, beating the consensus estimate of -CHF0.124 by CHF0.011.
Is Inogen overvalued?
According to Wall Street analysts Inogen’s price is currently Undervalued.
Does Inogen pay dividends?
Inogen does not currently pay dividends.
What is Inogen’s EPS estimate?
Inogen’s EPS estimate is -0.11.
How many shares outstanding does Inogen have?
Inogen has 26,538,338 shares outstanding.
What happened to Inogen’s price movement after its last earnings report?
Inogen reported an EPS of -CHF0.113 in its last earnings report, beating expectations of -CHF0.124. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inogen?
Currently, no hedge funds are holding shares in CH:6IO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inogen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF10.61 (― Upside)
CHF10.61 (― Upside)
Blogger Sentiment
Bullish
CH:6IO Sentiment 100%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inogen
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
6IO Company Deck
6IO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear commercial and product progress — notably strong international revenue growth (+15% YoY), continued POC unit expansion (>12% YoY), early traction for new products (Voxi shipments >5,000; Aurora account count doubled), margin improvement (adjusted gross margin +65 bps) and a raised adjusted EBITDA outlook. Offsetting these positives are ongoing headwinds in the U.S. DTC channel (U.S. sales -2% YoY), a 12% decline in rental revenue, a downward revision to full-year revenue guidance (midpoint reduction of ~ $11.5M), and continued dependency on distributor purchase timing and reimbursement/regulatory milestones. Overall the company shows momentum in strategic growth areas and improved unit economics, but macro and channel mix pressures keep near-term top-line growth constrained.View all CH:6IO earnings summaries